Tania Nazem, Ali Hosseini-Sharifabad, Mohammad Reza Mofid, Mohammad Hashemnia, Habib-Allah Nazem, Adel Mohammadalipour
{"title":"Investigating the Protective Role of Vitamin D Supplementation on Cyclophosphamide-Induced Liver Enzyme Alterations in Adult Male Rats.","authors":"Tania Nazem, Ali Hosseini-Sharifabad, Mohammad Reza Mofid, Mohammad Hashemnia, Habib-Allah Nazem, Adel Mohammadalipour","doi":"10.1055/a-2734-1920","DOIUrl":null,"url":null,"abstract":"<p><p>Cyclophosphamide is known to cause liver dysfunction. This study investigated the protective role of vitamin D supplementation against cyclophosphamide -induced liver dysfunction in adult male rats. The rats receiving cyclophosphamide were treated with vitamin D at doses of 1,000 and 3,000 IU/kg. At the end of the study period, biochemical and histopathological evaluations were conducted after the animals were sacrificed. The levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, nitric oxide, and bilirubin were significantly elevated in the cyclophosphamide group compared to the control group (<i>p</i><0.001). Conversely, these levels were significantly decreased in the vitamin D treatment groups (<i>p</i><0.01). Additionally, the activities of the catalase and glutathione peroxidase were significantly lower in the cyclophosphamide group than in controls (<i>p</i><0.01), while they increased significantly in the vitamin D groups (<i>p</i><0.001). According to a semi-quantitative scoring system, the highest scores for pathological lesions were observed in the cyclophosphamide group, with lower scores in the vitamin D groups. The differences between the cyclophosphamide group and both treated groups were statistically significant (<i>p</i><0.05). These results indicate that vitamin D, through its antioxidant properties, positively influenced liver enzyme levels altered by cyclophosphamide.</p>","PeriodicalId":11451,"journal":{"name":"Drug Research","volume":" ","pages":"20-27"},"PeriodicalIF":2.4000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1055/a-2734-1920","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/25 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
Cyclophosphamide is known to cause liver dysfunction. This study investigated the protective role of vitamin D supplementation against cyclophosphamide -induced liver dysfunction in adult male rats. The rats receiving cyclophosphamide were treated with vitamin D at doses of 1,000 and 3,000 IU/kg. At the end of the study period, biochemical and histopathological evaluations were conducted after the animals were sacrificed. The levels of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, nitric oxide, and bilirubin were significantly elevated in the cyclophosphamide group compared to the control group (p<0.001). Conversely, these levels were significantly decreased in the vitamin D treatment groups (p<0.01). Additionally, the activities of the catalase and glutathione peroxidase were significantly lower in the cyclophosphamide group than in controls (p<0.01), while they increased significantly in the vitamin D groups (p<0.001). According to a semi-quantitative scoring system, the highest scores for pathological lesions were observed in the cyclophosphamide group, with lower scores in the vitamin D groups. The differences between the cyclophosphamide group and both treated groups were statistically significant (p<0.05). These results indicate that vitamin D, through its antioxidant properties, positively influenced liver enzyme levels altered by cyclophosphamide.
期刊介绍:
Drug Research (formerly Arzneimittelforschung) is an international peer-reviewed journal with expedited processing times presenting the very latest research results related to novel and established drug molecules and the evaluation of new drug development. A key focus of the publication is translational medicine and the application of biological discoveries in the development of drugs for use in the clinical environment. Articles and experimental data from across the field of drug research address not only the issue of drug discovery, but also the mathematical and statistical methods for evaluating results from industrial investigations and clinical trials. Publishing twelve times a year, Drug Research includes original research articles as well as reviews, commentaries and short communications in the following areas: analytics applied to clinical trials chemistry and biochemistry clinical and experimental pharmacology drug interactions efficacy testing pharmacodynamics pharmacokinetics teratology toxicology.